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Abstract
In visceral leishmaniasis, the recovery from the disease is always associated with the generation of Th1-type of cellular
responses. Based on this, we have previously identified several Th1-stimulatory proteins of Leishmania donovani -triose
phosphate isomerase (TPI), protein disulfide isomerase (PDI) and elongation factor-2 (EL-2) etc. including heat shock protein
70 (HSP70) which induced Th1-type of cellular responses in both cured Leishmania patients/hamsters. Since, HSPs, being the
logical targets for vaccines aimed at augmenting cellular immunity and can be early targets in the immune response against
intracellular pathogens; they could be exploited as vaccine/adjuvant to induce long-term immunity more effectively.
Therefore, in this study, we checked whether HSP70 can further enhance the immunogenicity and protective responses of
the above said Th1-stimulatory proteins. Since, in most of the studies, immunogenicity of HSP70 of L. donovani was assessed
in native condition, herein we generated recombinant HSP70 and tested its potential to stimulate immune responses in
lymphocytes of cured Leishmania infected hamsters as well as in the peripheral blood mononuclear cells (PBMCs) of cured
patients of VL either individually or in combination with above mentioned recombinant proteins. rLdHSP70 alone elicited
strong cellular responses along with remarkable up-regulation of IFN-c and IL-12 cytokines and extremely lower level of IL-4
and IL-10. Among the various combinations, rLdHSP70 + rLdPDI emerged as superior one augmenting improved cellular
responses followed by rLdHSP70 + rLdEL-2. These combinations were further evaluated for its protective potential wherein
rLdHSP70 + rLdPDI again conferred utmost protection (,80%) followed by rLdHSP70 + rLdEL-2 (,75%) and generated a
strong cellular immune response with significant increase in the levels of iNOS transcript as well as IFN-c and IL-12 cytokines
which was further supported by the high level of IgG2 antibody in vaccinated animals. These observations indicated that
vaccine(s) based on combination of HSP70 with Th1-stimulatory protein(s) may be a viable proposition against intracellular
pathogens.
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Introduction
Visceral leishmaniasis (VL) or Kala-azar, one of the most
neglected tropical diseases, is caused by three leishmanial species,
L. donovani, L. infantum and L. chagasi depending on the
geographical area. L. infantum infects mostly children and
immunosuppressed individuals whereas L. donovani infects
individuals of all age groups. VL is endemic in 62 countries, with
a total of 200 million people at risk and estimated 500,000 new
cases of VL each year worldwide [1,2]. In India, kala-azar has
been reported mostly from the states of Bihar, Assam, West Bengal
and Eastern Uttar Pradesh. Currently available treatment for VL
is highly unsatisfactory due to their toxicities and side effects.
Besides, there are several reports of unresponsiveness to pentava-
lent antimonials (SbV) in recent years [3–5]. In a survey in Bihar,
there were a record alarming 100,000 cases of VL, of which
10,000 are unresponsive to SbV [6]. Therefore, this situation
demands for an alternative control strategy posing an urgent need
of a safe and effective vaccine, although, the development of an
effective Leishmania therapeutic/prophylactic vaccine has been a
challenge. Parasitic antigens that induce a significant level of
immune response have been primarily associated with the
identification of proteins that may be used for vaccine develop-
ment. Numerous studies showed antigens from different Leish-
mania spp. were able to stimulate IFN-c and IL-12 expression
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levels [7–11], the signatures for Th1 type of immune response [7–
9]. However, among these, only IFN-c represents the key cytokine
involved in the activation of macrophages for the killing of
Leishmania parasites [10,11]. Therefore, the Th1 feature of the
immune response could be exploited as vaccine candidates. Till
date besides killed or live-attenuated parasites, several Leishmania
antigens from different species either as DNA or as protein
vaccines were tested against VL with different level of success.
These observations provide sufficient evidences that a vaccine
against VL is feasible.
Based on this rationale, several potential immunogenic antigens
from L. donovani were identified through proteomics inducing
Th1 type immune response in the PBMCs of cured/endemic
Leishmania patients [12–14]. Heat shock protein 70 (HSP70) was
one amongst them identified as potential T-cell stimulatory protein
along with Aldolase, Enolase, P45, Protein Disulfide Isomerase
(PDI), Triose Phosphate Isomerase (TPI) and Elongation Factor-2
(EL-2). The Heat Shock Proteins (HSPs) are highly conserved
molecules and present in all eukaryotes and prokaryotes partic-
ularly localised in sub cellular region of parasites [15]. HSPs play
many important roles like folding, assembly, intracellular locali-
zation, secretion, and degradation of many proteins, hence HSPs
has been also termed as molecular chaperones [16]. Many studies
favor the involvement of chaperones in many immunological
processes such as in assembly of immunoglobulins, T-cell
receptors, and major histocompatibility complex (MHC) mole-
cules and participate in antigen processing and presentation
pathways [17–20]. The usage of HSP70 as a potent adjuvant in
immunotherapy of cancers and other infectious diseases has been
well documented [17,18,21–24]. The adjuvant effect of HSP70
has been demonstrated after immunization with Plasmodium
peptides [21], L. infantum [22] and L. donovani [23,24].
In most of the studies, immunogenicity of HSP70 of L.
donovani was assessed in native condition [23,25,26]. Herein,
we developed recombinant HSP70 of L. donovani and further
tested for its potential to stimulate immune responses in
lymphocytes of cured Leishmania infected hamsters as well as in
the peripheral blood mononuclear cells (PBMCs) of cured patients
of VL either individually or in combination with recombinant
proteins of L. donovani viz. PDI, TPI and EL-2 which were
identified earlier as potent Th1 stimulatory proteins through
immuno-proteomics and were found to be protective to hamsters
against Leishmania challenge [13,14,27–29]. Further, we exam-
ined the ability of above mentioned combinations, to protect the
hamsters against L. donovani challenges when administered as
recombinant protein vaccine.
Materials and Methods
Ethics Statement
Experiments on the animals (hamsters) were performed
following the approval of the protocol and the guidelines of
Institutional Animal Ethics Committee (IAEC) of the CDRI which
is adhered to National Guideline of CPCSEA (Committee for the
Purpose of Control and Supervision on Experiments on Animals)
under the Ministry of Environment and Forest, Government of
India. The approval reference number 154/10/Para/IAEC dated
04.10.10. The protocol and study with patients was approved by
the Ethics committee of the Kala-azar Medical Research Centre,
Muzaffarpur (Protocol # EC- KAMRC/Vaccine/VL/2007-01)
and written informed consent was obtained from patients before
enrolment to this study. All the human subjects underwent clinical
examination by a local physician for leishmanial and other
possible infections.
Host and Parasites
Golden hamsters (Mesocricetus auratus, 45–50 g) of either sex
were used for all experimental work. They were maintained in
climatically controlled room of animal house facility of Central
Drug Research Institute (CDRI) and were fed with standard
rodent food pellet (Lipton India Ltd.) and water ad libitum. The L.
donovani strain (2001) was procured from Institute of Medical
Sciences, BHU, Varanasi and was maintained in vitro as described
elsewhere [30]. L. donovani promastigotes were grown in RPMI-
1640 (Sigma-Aldrich, USA) at 26uC in 75 cm2 culture flasks
(Nunc, Denmark) [31]. Parasites were also maintained in hamsters
through serial passage i.e. from amastigote to amastigote in order
to maintain the virulence of parasite [31].
Preparation of soluble L. donovani promastigote antigen
Soluble L. donovani (SLD) promastigote antigen was prepared
as per the method described elsewhere [12,31]. Briefly, log phase
promastigotes (109) were harvested from 3 to 4 days old culture
and washed 3 to 4 times with cold phosphate-buffered saline (PBS)
and resuspended in PBS containing protease inhibitor cocktail
(PIC) (Sigma-Aldrich, USA) and subjected to ultrasonication and
centrifugation at 40,0006g for 30 min. The protein content of the
supernatant was estimated [32] and stored at 280uC.
Cloning, expression, purification and immunoblotting of
recombinant protein
Genomic DNA was isolated from L. donovani promastigotes
according to protocol described elsewhere [27]. HSP70 gene was
amplified using specific forward primer- 59-GGATCCATGA-
CATTCGACGGCGCCATG-39and reverse primer-59
GAATTCGTCCT TGCTCAGCCGGCCCT-39 which were
designed using L. major HSP70 gene sequence (accession
no. M36675.1) as template. The restriction sites for BamHI and
EcoRI are under lined in forward and reverse primers respectively.
The HSP70 gene was amplified using Taq DNA Polymerase
(Bangalore Genei, India) lacking 39–59 exonuclease activity in a
Thermocycler (Bio-Rad, USA). Amplified PCR product was first
cloned into the pTZ57R/T vector and then into bacterial
expression vector - pET28a+. Further, cloned insert was sequenced
and sequence submitted to the National Center for Biotechnology
Information (Accession no. HQ011382). The clone containing the
construct (rLdHSP70 + pET28a+) was used to express the L.
donovani HSP70 in E. coli Rosetta strain following induction with
1.0 mM isopropyl-b-D-thiogalacto-pyranoside (IPTG) at 37uC.
The recombinant protein was purified using Ni-NTA agarose
column (Qiagen Valencia, CA), following standard procedures
and lysis buffer as 50 mM Tris, 300 mM NaCl, 10 mM imidazole
and 10% glycerol (pH 8.0). Further, the purified protein was
analyzed by 12% SDS–PAGE, stained with coomassie brilliant
blue stain (Sigma-Aldrich, USA) and the protein content was
estimated by the Bradford method using bovine serum albumin
(BSA) as standard. The lipopolysaccharides (LPS) content of the
recombinant proteins was measured by Limulus amoebocyte
lysate test (QCL-1000, Lonza).
The purified rLdHSP70 protein was used for raising antibodies
in Swiss albino mice. Mice were immunized with 50 mg of
rLdHSP70 in combination of Freund’s complete adjuvant
following two booster doses of 25 mg of rLdHSP70 after 15 days
(two weeks interval) in combination of Freund’s incomplete
adjuvant and blood was collected for serum 8 days after the last
immunization. For immunoblotting experiment, purified
rLdHSP70 protein and SLD were resolved on 12% SDS–PAGE
and transferred to nitrocellulose membrane using a semi-dry blot
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apparatus (Amersham) [33]. Similarly, rLdHSP70 was transferred
to another set of membrane parallely. After overnight blocking in
5% BSA, both the membranes were incubated with antiserum to
the rLdHSP70 proteins (dilution of 1:4000) and serum (1:100)
from VL patient’s respectively for 2 h at room temperature (RT)
followed by three times washing with PBS containing 0.5%
Tween-20 (PBST). Further, the blot treated with antiserum to
rLdHSP70 was incubated with secondary antibody-goat anti-mice
IgG HRP conjugate (1:10,000) (Bangalore Genei, India) and blot
treated with patient’s serum was incubated with secondary
antibody- mouse anti-human IgG biotin conjugate (1:1000)
followed by HRP conjugated streptavidin (1:500) (BD Pharmin-
gen, USA) for 1 h at RT. Both the blots were developed by using
diaminobenzidine + imidazole + H2O2 (Sigma-Aldrich, USA).
However, cloning, expression and purification of L. donovani
Triose phosphate Isomerase (LdTPI) Protein Disulfide Isomerase
(LdPDI) and Elongation Factor 2 (LdEL-2) were done earlier [27–
29]. Further, all these recombinant proteins were purified
following the reported protocol.
Treatment of L. donovani infected hamsters and isolation
of mononuclear cells from lymph node
Approximately 30 hamsters were infected with 107 amastigotes
intracardially and checked for parasite burden as described
elsewhere [13]. Animals harbouring .20–25 amastigotes/100
macrophage cell nuclei were then treated with miltefosine
(SynphaBase, Switzerland) given orally @ 40 mg/kg bodyweight
for 5 days. Animals were reassessed for complete cure by splenic
biopsy performed on day 30 post treatment. Mononuclear cells
were separated from lymph nodes of cured, infected as well as
from normal hamsters as per the protocol of Garg et al. [30].
Finally a suspension of 106 cells/ml was made in cRPMI (Sigma-
Aldrich, U.S.A) which were further utilized for lymphoprolifera-
tive assay and for the estimation of NO production.
Isolation of peripheral blood mononuclear cells (PBMCs)
from different groups of human patients
The study groups for human samples were as follows:
[1] Eight cured patients (5 males +3 females, age range 5–32
years) from hyper-endemic areas of Bihar. All the patients had
received complete course of miltefosine treatment and had
recovered from VL. Diagnosis was established in all cases by
demonstration of parasites in splenic aspirates and found
negative at the time of study.
[2] Eight endemic household contacts (6 males +2 females, age
ranging from 8 to 35 years) who neither showed clinical
symptoms nor received any treatment for Kala-azar.
[3] Eight infected patients (4 males +4 females, age range 5–49
years) showing clinical symptoms of Kala-azar.
[4] Eight normal healthy donors (4 males +4 female, age range
25–32 years) from non-endemic areas, without any history of
leishmaniasis, served as negative control.
Heparinised venous blood (10 ml each) was collected from all
study subjects and peripheral blood mononuclear cells (PBMCs)
were isolated from blood by Ficoll Hypaque density gradient
centrifugation (Histopaque 1077, Sigma-Aldrich, USA) as de-
scribed by Garg et al [30]. A final suspension of 16106 cells/ml
was made in cRPMI (Sigma-Aldrich, USA) after determining cell
viability by trypan blue (Sigma-Aldrich, USA) staining method.
Vaccination with rLdHSP70 alongwith its various
combinations (rLdHSP70 + rLdPDI, rLdHSP70 + rLdTPI,
rLdHSP70 + rLdEL-2) in hamsters
Eleven groups of hamsters containing 15–20 animals per group,
were taken for the study, wherein groups 1–4 served as controls
i.e.- group-1, non-vaccinated and unchallenged (normal control);
group-2, non-vaccinated and challenged (infected control); group-
3, BCG alone and group-4 rLdHSP70 alone. The animals of
group 5-8 were vaccinated intradermally (i.d.) with a dose of
50 mg/50 ml of either recombinant proteins rLdHSP70/rLdPDI/
rLdTPI/rLdEL-2 along with equal volume of 0.1 mg per animal
BCG respectively and group 9-11 were vaccinated with combi-
nations viz. rLdHSP70 + rLdPDI, rLdHSP70 + rLdTPI,
rLdHSP70 + rLdEL-2. After fourteen days a booster dose of half
of the amount of recombinant proteins along with BCG was given
i.d. route to all the hamsters of Group 5–8, only BCG to the
animals of group-3, only rLdHSP70 to group-4. Similarly all the
hamsters of group 9–11 were vaccinated with booster dose of their
respective combinations. After 21 days the hamsters of Groups 2–
11 were challenged intracardially (i.c.) with metacyclic promasti-
gotes (107) of L. donovani. After post challenge (p.c), on the day
45, 60, 90 and 120, three to four hamsters from each group were
sacrificed for the assessment of parasitological and immunological
(cytokines by real-time PCR and antibody level by ELISA and
lymphoproliferation and NO production by earlier mention
methods) progression of VL. The impression smears of different
organs, such as spleen, liver, and bone marrow of experimental
animals were made, and the criteria for the assessment of parasitic
burden was based on the counting of the number of amastigotes
per 100 cell nuclei in each organ. The percentage of inhibition (%
inhibition) of parasite multiplication was calculated in comparison
with the non-vaccinated control using the following formula: %
inhibition = (number of amastigote count from infected control -
number of amastigote from the vaccinated group/number of
parasite count from infected control) 6100. Animals of all the
groups were given proper care and observed for their survival
period.
Immunological assays
Delayed type hypersensitivity (DTH). DTH was per-
formed by injecting 50 mg/50 ml of SLD in PBS via i.d route
into one footpad and PBS alone into another footpad of each of
the vaccinated and unvaccinated controls. The response was
evaluated 48 h later by measuring the difference in footpad
swelling between the two, with and without SLD for each animal
[8].
Lymphocyte proliferation and nitric oxide assay. These
assays were carried out as per the protocol described by Garg et al
[34] with slight modifications. PBMCs and mononuclear cells
(16106 cells/ml) of cured/endemic/infected patients as well as
cured/normal/infected hamsters respectively, were cultured in 96-
well flat bottom tissue culture plates (Nunc, Denmark). About
100 ml of predetermined concentration of mitogens phytohaem-
agglutinin (PHA, 10 mg/ml Sigma-Aldrich, USA) for patient’s
PBMCs, concanavalin A (ConA, 10 mg/ml, Sigma-Aldrich, USA)
for hamster’s mononuclear cells, as well as rLdHSP70, rLdPDI/
rLdTPI/rLdEL-2 and combinations (rLdHSP70 + rLdPDI,
rLdHSP70 + rLdTPI, rLdHSP70 + rLdEL-2) and SLD (10 mg/
ml each) were added to the wells in triplicate. Wells without
stimulants served as blank controls. PHA and ConA were served as
positive control for proliferation in human patients PBMCs and
hamster’s lymphocytes, respectively. Cultures were incubated at
37uC in a CO2 incubator with 5% CO2 for 3 days in case of
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mitogens as control, and for 5 days in case of test antigens (i.e.
recombinant proteins). Eighteen hours prior to termination of
experiment, 50 ml of XTT (Roche Diagnostics) was added to
100 ml of supernatants of each well and absorbance was measured
at 480 nm with 650 nm as reference wavelength.
Similarly nitric oxide (NO) estimation was done using standard
control mitogens (LPS, 10 mg/ml). NO level was assessed using
Griess reagent (Sigma-Aldrich, USA) in the culture supernatants of
naive hamster peritoneal macrophages [30] after the exposure
with 100 ml supernatant of stimulated mononuclear cells. The
supernatants (100 ml) collected from macrophage cultures 24 hrs
after incubation was mixed with an equal volume of Griess reagent
(Sigma-Aldrich, USA) and left for 10 min at RT. The absorbance
of the reaction was measured at 540 nm in an ELISA reader as
described elsewhere [35].
Estimation of cytokine levels- IFN-c/IL-12/IL-10/IL-4 in
lymphocytes of cured and endemic patients. PBMCs
(16106 cells/ml) from human patients were plated in 96-well
culture plates and the recombinant protein rLdHSP70 and its
combination with rLdPDI, rLdTPI, and rLdEL-2 were added at a
concentration of 10 mg/ml in triplicate wells. The level of IFN-c,
IL-12, IL-4 and IL-10 was estimated after 5 days of incubation
with antigen using supernatants by enzyme-linked immunosorbent
assay kit (OptEIA kit, BD Pharmingen, USA). The results were
expressed as pg/ml. The lower detection limits for various
cytokines were as follows: 5.1 pg/ml for IFN- c, 30.8 pg/ml for
IL-12, 5.1 pg/ml for IL-4 and 6.9 pg/ml for IL-10.
Quantification of mRNA cytokines and inducible NO
synthase (iNOS) by quantitative real time PCR in
vaccinated hamsters. qRT-PCR was performed to assess the
mRNAs expression profile for various cytokines and iNOS in
splenocytes of hamsters. Total RNA was isolated from splenic
tissues using Tri-reagent (Invitrogen, USA) as described elsewhere
[27]. One microgram of total RNA was used for the synthesis of
cDNA using a first-strand cDNA synthesis kit (Fermentas, USA).
For real-time PCR, primers were designed using Beacon Designer
software (Bio-Rad, USA) based on the cytokines and iNOS mRNA
sequences available on PubMed [36] (Table 1). qRT-PCR was
performed as per the protocol described earlier by Samant et al
[37]. Briefly, it was carried out with 12.5 ml of SYBR green PCR
master mix, 1 mg of cDNA, and primers at a final concentration of
300 nM in a final volume of 25 ml. PCR was performed under the
following conditions: initial denaturation at 95uC for 2 min
followed by 40 cycles, each consisting of denaturation at 95uC
for 30 s, annealing at 55uC for 40 s, and extension at 72uC for
40 s per cycle using the iQ5 multicolour real-time PCR system
(Bio-Rad, USA). cDNAs from infected control hamsters were used
as ‘‘comparator samples’’ for quantification of those corresponding
to test sample. The normalization of all the quantifications was
done by using housekeeping gene Hypoxanthine phosphoribosyl
transferase (HPRT). A negative control (without c-DNA) was used
to eliminate nonspecific reactions. The cycle threshold (CT) value
was defined as the number of PCR cycles required for the
fluorescence signal to exceed the detection threshold value
(background noise). Differences in gene expression were calculated
by the comparative CT method as described earlier [37] wherein
test samples compared to a comparator sample. Results are
expressed as the degrees of difference between DCT values of test
and comparator samples.
Measurement of serum antibody response in vaccinated
hamsters. The level of immunoglobulins, IgG and its isotypes
in the serum sample of hamsters of different experimental groups
was measured as per protocol by Samant et al [37] with slight
modifications. Briefly, 96-well ELISA plates (Nunc, Denmark)
were coated with 0.2 mg/100 ml/well recombinant proteins
followed by incubation at 4uC and blocking with 1.5% BSA. Sera
from different vaccinated groups were used at a dilution of 1/100
for IgG, IgG1, and IgG2 and kept for 2 h at RT. Biotin
conjugated mouse anti-Armenian and Syrian hamster IgG, IgG1
and IgG2 (BD Pharmingen, USA) were added for 1 h at room
temperature at 1/1000 dilutions and were further incubated with
peroxidase-conjugated streptavidin at 1/1000 (BD Pharmingen,
USA) for 1 h. Finally, the substrate O-phenylenediamine dihy-
drochloride (Sigma-Aldrich, USA) was added and the plate was
read at 492 nm.
Statistical analysis
Data were expressed as mean6 S.D. In each experiment 15–20
animals were used in each group. Two sets of experiments were
performed independently and the results were analyzed by one-
way ANOVA test using Prism Graphpad software program. The
upper level of significance was chosen as P,0.001 (highly
significant).
Results
LdHSP70 was cloned, sequenced and expressed in E.coli
Rosetta strain
The LdHSP70 (1548 bp) gene of L. donovani was successfully
cloned in T/A vector and sequenced. The homology of LdHSP70
has been found to the tune of 98% with L. infantum and L. major
and 99% with L. mexicana. Consequently, LdHSP70 was further
sub-cloned in bacterial expression vector pET28a+ (Fig. 1A),
purified by affinity chromatography using Ni2+ NTA agarose
beads containing columns and eluted at 250 mM imidazole
concentration. The size of the eluted rLdHSP70 proteins was
,60 kDa (Fig. 1B) which was further confirmed by western blot
with anti-serum antibody raised in Swiss mice. Immunoblot
analysis of SLD of L. donovani promastigote with the polyclonal
anti-rLdHSP70 antibody detected the band beloning to 72 kDa in
SLD (Fig. 1C). Western blot analysis of rLdHSP70 with patients
sera also showed a dominant protein band of ,60 kDa (Fig. 1D).
The results showed that the recombinant was correctly constructed
and expressed in bacterial expression vector.
Combination of rLdHSP70 + rLdPDI stimulated optimum
lymphoproliferative response and NO production in
Cured Leishmania infected hamsters
The cellular responses of lymph node cells of cured hamsters
were assessed for lymphoproliferative response and NO produc-
tion against the mitogens - ConA or LPS; and antigens – SLD as
well as recombinant proteins (rLdHSP70, rLdPDI, rLdTPI,
rLdEL-2) either alone or in combinations with rLdHSP70. The
comparison of lymphoproliferative (LTT) response of cured
lymphocytes was done with that of normal as well as L. donovani
infected lymphocytes, which served as controls. The rLdHSP70
alone stimulated ,2 fold better proliferative response than SLD in
mononuclear cells of cured hamsters, while among the various
combinations tested along with - rLdPDI, rLdTPI and rLdEL-2,
stimulation with rLdHSP70 + rLdPDI induced optimum prolif-
erative responses (,4 folds) followed by rLdHSP70 + rLdEL-2
(,3 folds) and rLdHSP70 + rLdTPI (,2.8 folds) when compared
with SLD (Fig. 2A). Moreover, when compared to rLdHSP70
alone the combination of rLdHSP70 + rLdPDI induced significant
proliferative responses (,2.2 folds) (p,0.001). On contrary, other
recombinant proteins individually have also shown lesser LTT
response when compared to various combinations tested (Fig. 2A).
Protective Responses of Th1 Stimulatory Proteins of L. donovani
PLOS ONE | www.plosone.org 4 September 2014 | Volume 9 | Issue 9 | e108556
Similarly, rLdHSP70 + rLdPDI stimulated optimum NO produc-
tion (,1.5 folds) in peritoneal macrophages of cured hamsters (p,
0.001) as compared to rLdHSP70 followed by rLdHSP70 +
rLdTPI, and rLdHSP70 + rLdEL-2 (Fig. 2B).
Combination of rLdHSP70 + rLdPDI as well as rLdHSP70 +
rLdEL-2 stimulated PBMCs from Leishmania patients
optimally to proliferate and to stimulate dominant
Thl- cytokine release
We further corroborated the proliferative responses and
cytokine production of the various combinations as well as
individual recombinant proteins in PBMCs of cured Leishmania
infected patients. The comparison was made with the PBMCs
from cured patients with L. donovani infected/endemic/normal
groups. All the individuals in each study group were found to
shown different responses. Endemic control and cured kala-azar
patients groups have shown higher mean O.D value against PHA
(2.29160.159 and 2.80760.275 respectively) as compared to
unstimulated control. The combinations of rLdHSP70 + rLdPDI
as well as rLdHSP70 + rLdEL-2 exhibited considerably better
LTT response (,3.2 and ,3.0 folds respectively) as compared to
SLD. Moreover, the two combinations stimulated considerably
better LTT responses (,1.5–2 folds) as compared to rLdHSP70,
which was found statistically significant (p,0.001) in all the cured
patients groups (Fig. 3A). In addition, the same combinations
stimulated PBMCs of cured patients for higher NO production
(,2.4, and ,2 folds respectively) as compared to SLD which was
also significantly better as compared to rLdHSP70 (Fig. 3B).
We further assessed the production of Th1/Th2 cytokine levels
in PBMCs from cured patients in response to the various
combinations. The level of IL-12 and IFN-c, the signatures of
Th1 type of response, were noticed to be higher in the supernatant
Table 1. Sequences of forward and reverse primers of hamster cytokines used for quantitative real time PCR (qRT-PCR).
S.No. Primer Primer sequence
1 HGPRT FP 59 GATAGATCCACTCCCATAACTG 39
HGPRT RP 59 TACCTTCAACAATCAAGACATTC 39
2 IFNc FP 59 GCTTAGATGTCGTGAATGG 39
IFNc RP 59 GCTGCTGTTGAAGAAGTTAG 39
3 IL-12 FP 59 TATGTTGTAGAGGTGGACTG 39
IL-12 RP 59 TTGTGGCAGGTGTATTGG 39
4 IL-4 FP 59 GCCATCCTGCTCTGCCTTC 39
IL-4 RP 59 TCCGTGGAGTTCTTCCTTGC 39
5 IL-10 FP 59 TGCCAAACCTTATCAGAAATG 39
IL-10 RP 59 AGTTATCCTTCACCTGTTCC 39
6 iNOS FP 59 CGACGGCACCATCAGAGG 39
iNOS RP 59 AGGATCAGAGGCAGCACATC 39
doi:10.1371/journal.pone.0108556.t001
Figure 1. Molecular characterization of L. donovani Heat Shock Protein70 (LdHSP70). (A) Clone confirmation of LdHSP70 in pET28a+
vector. M: 1 kb molecular mass marker; Lane1: Undigested pET28a+-LdHSP70; Lane2: BamHI and EcoRI digested pET28a+-LdHSP70; (B) Expression,
purification and elution of rLdHSP70 at 200 mM of imidazole concentration (conc.) and separation in 12%SDS PAGE. M: molecular weight markers,
Lane 1: whole cell lysate (WCL) of uninduced E.coli; Lane 2: WCL of E.coli induced at 37uC and 1 mM IPTG; Lane 3: soup of protein; Lane 4: flow
through fraction from column; Lane 5 and 6: wash fraction at 10 mM & 50 mM imidazole conc. respectively; Lane 7, 8 and 9: purified protein fractions;
(C) Western blot analysis using anti rLdHSP70 antibody; M: molecular mass marker; Lane1: WCL without IPTG induction; Lane 2: WCL with IPTG
(1 mM) induction at 37uC, Lane 3: purified protein; Lane 4: soluble L. donovani; (D) Western blot analysis of rLdHSP70 with patients serum. M:
molecular mass marker; Lane 1: blot with rLdHSP70.
doi:10.1371/journal.pone.0108556.g001
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of cured patients against rLdHSP70 and the combinations with
rLdHSP70. Though rLdHSP70 itself induced moderate level of
IFN-c response (,2.8 folds) while in combinations, rLdHSP70 +
rLdPDI and rLdHSP70 + rLdEL-2 induced maximum level of
IFN-c response (,5.4 and ,5.8 folds respectively) followed by
rLdHSP70 + rLdTPI (,4.4 folds) in comparison to SLD. The
induction level of IFN-c in response to the combinations,
rLdHSP70 + rLdPDI and rLdHSP70 + rLdEL-2 was found to
be ,2 folds higher than rLdHSP70 itself. Similarly, it was
observed that level of IL-12 was comparatively higher against
rLdHSP70 + rLdPDI (,4 folds) in comparison to SLD which was
also higher (,2 folds) as compared to rLdHSP70 alone
(Fig. 4A&B). On the other hand, very low level of IL-4 cytokine
was detected in supernatant of cured patients against rLdHSP70 +
rLdPDI (,6.2 folds) followed by rLdHSP70 + rLdTPI (,4.4 folds)
and rLdHSP70 + rLdEL-2 (,3.4 folds) in comparison to SLD.
However, the combination of rLdHSP70 + rLdPDI has shown
higher level of IL-4 down regulation than rLdHSP70. Similarly,
IL-10 level was also down regulated but its level was lower in
comparison to IL-4. PBMCs of cured/endemic contacts generated
a mixed type of Th1/Th2 cytokine response against SLD wherein
high levels of IL-10 and IL-4 and comparatively low level of IFN-c
and IL-12 were noticed in response to rLdHSP70 (Fig. 4C & D).
The result represents that recombinant Th1 protein in combina-
tion with rLdHSP70 performed as dominant T-cell antigens to
which majority of the cured patients PBMCs have responded
positively.
Vaccination with rLdHSP70 + rLdPDI and rLdHSP70 +
rLdEL-2 offered maximum protection against L. donovani
challenge in Hamsters
Since, in vitro studies on cured hamster’s/patient’s lymphocytes
have revealed that Th1 stimulatory proteins - rLdPDI, rLdTPI
and rLdEL-2, in combination with rLdHSP70 were able to
generate a strong Th1-type immune response, we further
evaluated the same combinations for their prophylactic efficacies
in hamsters against L. donovani challenges. The animals
Figure 2. Cellular responses of the combinations rLdHSP70 + rLdPDI/rLdHSP70 + rLdTPI/rLdHSP70 + rLdEL-2 in hamsters
lymphocytes (lymph node cell). (A) LTT response of mononuclear cells from normal, L. donovani infected (25 day p.c.) and treated hamsters in
response to Con A, SLD and combinations (rLdHSP70 + rLdPDI/rLdHSP70 + rLdTPI/rLdHSP70 + rLdEL-2) at 10 mg/ml each. Proliferative response was
represented as mean O.D of stimulated cells - mean O.D of unstimulated control cells. Each bar represents the pooled data (mean 6 S.D. value) of 6
hamsters and the data represent the means of triplicate wells 6 S.D. of each hamster as mean O.D of stimulated cells and mean O.D of unstimulated
control cells. (B) Nitric oxide production (mM): Peritoneal macrophages were stimulated with the supernatants of stimulated lymphocytes (3 days
for mitogen and 5 days for test antigens) of normal, infected and cured hamsters in response to combinations with rLdHSP70, SLD and LPS
respectively at 10 mg/ml each. The estimation of NO production was done using Greiss reagent in supernatants collected from macrophage cultures
24 h after incubation and the absorbance of the reaction product was measured at 540 nm. Significance values indicate the difference between the
SLD and combination with rLdHSP70 stimulation (*, p,0.05, **, p,0.01; ***, p,0.001).
doi:10.1371/journal.pone.0108556.g002
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vaccinated with the combinations viz. rLdHSP70 + rLdPDI,
rLdHSP70 + rLdTPI and rLdHSP70 + rLdEL-2 have shown
considerably good prophylactic efficacy to tune of 80%, 70%, and
74% respectively, against L. donovani challenges. On the other
hand, when the recombinant proteins viz. rLdPDI, rLdTPI and
rLdEL-2 were used along with BCG as an adjuvant for
vaccination, the prophylactic efficacy was found to be similar as
in combination with rLdHSP70. In general, all the vaccinated
groups have shown decreased parasitic burden in spleen, liver and
bone marrow onwards from day 45 to day 90 p.c. and was
observed very low on day 90 p.c (p,0.001) (Fig 5A–C). Moreover,
the hamsters vaccinated with all these combinations gained in
body weight as compared to the control groups, when kept
simultaneously up to day 90 post challenge (p.c.) (Fig. 6A).
Further, an increase in the weight of spleen and liver was also
observed in the above stated vaccinated animals. When hamsters
were vaccinated with either rLdHSP70 or BCG, no reduction in
parasite load was observed. However, the combination of
rLdHSP70 + BCG has yielded moderate level (,65%) of
prophylactic efficacy. Moreover, all the vaccinated hamsters
survived longer after the lethal challenge of L. donovani and
remained healthy until the termination of the experiment 6–10
months post-infection. Among all the vaccinated groups, the
hamsters vaccinated with rLdHSP70 + rLdPDI, survived and
remained healthy till 10 months post-challenge (Fig. 7). Whereas,
the hamsters of other vaccinated groups (except BCG or
rLdHSP70 vaccinated and infected controls) could survive and
remained healthy up to 6 months post-challenge (Fig. 7). On the
other hand, there was progressive increase in parasite load in the
hamsters immunized with either BCG or HSP70 alone as well as
unimmunized ones and they succumbed to virulent L. donovani
challenge within 2–3 months.
Vaccination with the combinations, rLdHSP70 + rLdPDI,
rLdHSP70 + rLdTPI, rLdHSP70 + rLdEL-2 stimulates
Leishmania-specific cellular responses
The cellular responses generated following vaccination with
various combinations in hamsters and challenged with L.
donovani were characterized. The LTT response of the lymph
node cells from vaccinated hamsters upon stimulation with ConA
was observed to be similar to those of the normal animals
throughout the entire post challenged period (days 45, 60, 90 p.c.).
In antigen-specific re-stimulation assays, the lymph node cells from
hamsters vaccinated with the combinations viz. rLdHSP70 +
rLdPDI, rLdHSP70 + rLdTPI and rLdHSP70 + rLdEL-2 showed
an enhanced (,6.5,,3.0 and,6.0 folds respectively) proliferative
Figure 3. Cellular responses of the combinations rLdHSP70 + rLdPDI/rLdHSP70 + rLdTPI/rLdHSP70 + rLdEL-2 in patients sample. (A)
LTT response of PBMC from L. donovani infected, endemic and cured patients in response to PHA, SLD and recombinant test antigens individually
and in combination with rLdHSP70 10 mg/ml each. Proliferation was represented as mean O.D of stimulated cell - mean O.D of unstimulated control.
Each bar represents the pooled data (mean 6 S.D. value) of stimulated PBMCs of each group. (B) Significance values indicate the difference between
the SLD and rLdHSP-70/rLdPDI/rLdTPI/rLdEL-2 and rLdHSP-70 + rLdPDI/rLdHSP-70 + rLdTPI/rLdHSP-70 + rLdEL-2 stimulation (*, p,0.05**, p,0.01;
***, p,0.001).
doi:10.1371/journal.pone.0108556.g003
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response than non-vaccinated infected control hamsters, on day 90
p.c.(p,0.001) (Fig. 8B). On the other hand, there was lesser
proliferative response in animals vaccinated with BCG or
rLdHSP70 alone as well as non-vaccinated infected control.
Since, generation of nitric oxide (NO) after macrophage
activation by IFN-c is an important factor in controlling
leishmaniasis [38], the level of NO content in lymph node cells
was measured in all the vaccinated hamsters and challenged with
L. donovani. Hamsters vaccinated with all the three combinations
viz. rLdHSP70 + rLdPDI, rLdHSP70 + rLdTPI, rLdHSP70 +
rLdEL-2 showed an increase (,6.0, ,7.5 and ,3.0 folds,
respectively) in the level of NO production (p,0.001) on day 90
p.c (Fig. 8D) as compared to non-vaccinated infected control
group of hamsters.
DTH is an index of cell mediated immunity in vivo. The
hamsters vaccinated with various combinations elicited significant
level of DTH response as compared to the other control groups on
day 90 p.c. as compared to the infected control groups. However,
all the hamsters vaccinated with various combinations have shown
almost comparable DTH response (Fig. 8E).
Vaccination with the combinations, rLdHSP70 + rLdPDI,
rLdHSP70 + rLdTPI, rLdHSP70 + rLdEL-2 favours Th1-type
cytokine responses as determined by real-time PCR
Since, cured Leishmania infected patients PBMCs elicited Th1-
type of immune responses against all the combinations viz.
rLdHSP70 + rLdPDI, rLdHSP70 + rLdTPI, rLdHSP70 + rLdEL-
2 we further assessed the cytokine responses in hamsters
vaccinated with these combinations. The mRNA expression level
of the Th1 and Th2 cytokines in vaccinated group of hamsters was
estimated by qRT-PCR, on days 45 and 90 p.c. A moderate
increase (,2 to ,3 folds) in expression levels of iNOS mRNA
Figure 4. Cytokine production. (A) IL-12, (B) IFN-c, (C) IL-10, and (D) IL-4, in PBMCs from individuals of cured VL patients (n = 8) and endemic
controls (n = 8) in response to recombinant proteins individually as well as their combinations with rLdHSP70 and SLD antigens, each data point
represents one individual. The results were expressed as picograms (pg) of cytokine/ml, based on the standard curves of the respective cytokine
provided in the kit. The lower detection limits for various cytokines were as follows: for 5.1 pg/ml for IFN- c, 30.8 pg/ml for IL-12, 5.1 pg/ml for IL-4
and 6.9 pg/ml for IL-10. Values are given as concentration in pg/ml.
doi:10.1371/journal.pone.0108556.g004
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transcripts, which is known to impart major role in control of
leishmaniasis, was observed in all the hamsters vaccinated with
above mentioned combinations on day 45 p.c., which was further
increased significantly (,3 to ,4 folds) on day 90 p.c., as
compared to non-vaccinated infected control (Fig. 9A&B). Simi-
larly, one of the healing inflammatory cytokine IL-12 was found to
be significantly up-regulated upto ,8 folds on day 90 p.c. (p,
0.001) in rLdHSP70 + rLdPDI vaccinated hamsters followed by
rLdHSP70 + rLdEL-2 vaccinated (,6.5 folds), as compared with
infected control (Fig. 9C&D). At the same time point, the
expression of IFN-c was also higher (,5 folds) in rLdHSP70 +
rLdPDI vaccinated hamsters followed by vaccination with
rLdHSP70 + rLdEL-2 (,3.5 folds) in comparison to L.
donovani-infected group (Fig. 9E&F). On the contrary, these
Figure 5. Prophylactic efficacy of combinations in hamsters against L. donovani challenge. Leishmania parasite burden (number. of
amastigotes per 1000 cell nuclei) in the dab smears of spleen (A), liver (B) and bone marrow (C) of hamsters on days 45, 60, 90, and 120 post
challenge (p.c.) Since the non-vaccinated challenged (infected control) and the Bacillus Calmette Guerin (BCG) alone/rLdHSP70 alone vaccinated and
challenged group died after day 90 (D90) of the study period, their corresponding bars are not depicted in A, B and C. Significance values indicate the
difference between the vaccinated and infected group (*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0108556.g005
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Th1 cytokines were down-regulated in infected control groups
whereas, Th2 cytokines viz. IL-4 and IL-10 were significantly up-
regulated in infected control groups, indicating progressive VL
whilst these cytokines were highly down-regulated in vaccinated
animals reflecting the situation in cured VL (Fig. 9G–J).
Serological responses (Leishmania-specific IgG and its
isotypes) in vaccinated hamsters
We further checked for antibody levels in the serum of
vaccinated animals in comparison to infected control animals.
Although it is well known that the cytokines such as IFN-c and IL-
4 regulate immunoglobulin class switching of IgG2 and IgG1
Figure 6. Prophylactic efficacy of combinations in hamsters against L. donovani challenge. Body weight (A), liver weight (B) and spleen
weight (C), of hamsters in gram (gm) on days 0, 45, 60, 90 and 120 p.c. Since infected control, the BCG alone/rLdHSP70 alone vaccinated and
challenged group died after day 90 (D 90) of the study period, their corresponding bars are not shown in A, B and C. Significance values indicate the
difference between the vaccinated and infected group (*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0108556.g006
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respectively, in this study the level of IgG2 was found elevated up
to ,5 folds in animals vaccinated with rLdHSP70 + rLdPDI,
rLdHSP70 + rLdTPI, rLdHSP70 + rLdEL-2, BCG + rLdPDI,
BCG + rLdTPI and BCG + rLdEL-2 over the others on day 90
p.c., which is indicative for Th1-type immune response (Fig. 10F).
Higher levels of IgG1 were observed in the infected control
animals. As a measure of CMI, the elevated level of IgG2 was
consistent with the development of effective immune responses.
Discussion
During the course of infection of mammalian hosts with either
intracellular or extracellular pathogens, HSPs become most
important targets of the immune response [39–44]. In case of
intracellular organisms, particularly, Leishmania spp., Plasmodium
spp., Trypanosoma cruzi, and Mycobacterium spp., immune
responses to HSP at both B- and T- cell levels have been
described [39,41,42,44]. Further, HSP mediate essential cytopro-
tective function, like production of cytokines, provide maturation
signals and facilitate peptides to antigen presenting cells through
receptor-mediated interactions. Therefore, all these functions
favor HSPs as potential immunoregulatory agents and thus allow
their exploitation for the development of a new generation
therapeutic and prophylactic vaccine against infectious diseases
[45–48]. Among the various studied HSP families, the HSP70
family is well characterized and has attracted much attention
because of its versatile functions in the immune system. It is
considered as the ‘workhouse’ of the chaperons, because of its
promiscuity to assist in folding new polypeptide chains [49–51].
Besides the chaperone activity, HSP70 molecules can function as
an adjuvant also [52,53]. The use of novel vaccine adjuvants or
carrier proteins, which are known to enhance the immunogenicity
of the subunit antigens and provide T-cell help, can improve the
potency of vaccines. The potential of HSP70 to function as
adjuvants when fused to or co-delivered with protein antigens,
make them attractive vaccine candidates [22,24,54–57].
The cure of VL is always associated with the induction of Th1
cytokines dominated by IFN-c. Based on this fact, our earlier
studies showed that a sub-fraction of L. donovani soluble protein
ranging from 89.9 to 97.1 kDa, to be T-cell stimulatory and
protective against experimental VL [12–14]. This sub-fraction,
when subjected to proteomic analysis, revealed several Th1
stimulatory proteins including HSP70. Bhowmick et al. [26] and
Kaur et al [23,24] have earlier evaluated native HSP70 protein of
L. donovani, for its immunogenicity and protective potential using
electro-elution method. Herein, we successfully cloned, expressed
and purified the HSP70 protein of L. donovani in order to obtain
protein in large quantity for immunological characterization. In
another study, cloning, expression and purification of L. donovani
specific 70 kDa protein was done for the purpose of serodiagnosis
of VL wherein the primers were designed on the basis of sequence
of the peptide, identified from the immunogenic protein fraction
corresponding to a HSP of MW 70 kDa containing 653 amino
acids through MALDI TOF analysis [58,59]. In our study, the
HSP70 gene sequence analysis of L. donovani through nBLAST
showed ,98% identity with L. major and L. infantum and ,99%
homology with L. mexicana. Similarly, a comparative sequence
analysis with human HSP70 revealed ,72% homology.
It is well-known that a Th1 response is generated with increased
production of IL-12 and IFN-c and increased level of NO synthase
in cured patients who has become immune to re-infection with
Leishmania [7,8,34,60,61]. Therefore, the antigens that are
involved in the stimulation of Th1 cell and initiation of memory
Th1 cells can be considered for suitable vaccine candidate against
VL. Further, unlike rodents, particularly mice, human VL has
been demonstrating both Th1 and Th2 type immune responses,
where protective immunity is achieved by polarization of immune
response towards Th1 [62]. The clinicopathological profile of
hamsters infected with L. donovani, however, closely mimics to
human VL resulting in a persistently increasing parasite burden,
progressive cachexia, hepato-splenomegaly, pancytopenia, hyper-
gammaglobulinemia and ultimately death [30,36,63,64]. Since,
HSP70 was identified as Th1 stimulatory protein, we therefore,
evaluated rLdHSP70 of L. donovani for its ability to stimulate cell
proliferation and cytokine production on PBMCs from cured
hamster as well as cured kala-azar patients infected with L.
donovani and compared it with SLD. In addition, since, many
Figure 7. Survival curve analysis of different experimental groups. Survival of animals (6 hamsters in each experimental group) was
observed up to day 300 p.c.
doi:10.1371/journal.pone.0108556.g007
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workers have explored the adjuvant property of HSP70 which
elicit strong humoral and cellular immune response when it is
either fused or mixed with other antigens [22–24,57,65–71], the
activity of rLdHSP70 was also simultaneously evaluated in
combination with the potential Th1 proteins (rLdPDI, rLdTPI
and rLdEL-2) identified in our laboratory [12]. rLdHSP70
stimulated significant lymphoproliferative response in cured
hamsters/human as compared to SLD. It further induced
optimum proliferative response when combined other Th1
proteins- rLdPDI, rLdTPI and rLdEL-2 wherein, among the
three the combination of rLdHSP70 + rLdPDI exhibited better
cellular responses. Further, since, in human as well as in
experimental leishmaniasis, immunity is primarily mediated by
T lymphocyte [72] which contributes in the immune response to
L. donovani infection by producing cytokines which seems to be
essential mediators of immunity to Leishmania [9], we character-
ized the cytokine responses in cured Leishmania patients/endemic
contacts following stimulation with rLdHSP70 alone or in
combinations with rLdPDI, rLdTPI and rLdEL-2. All the
stimulants showed considerably good Thl cytokine responses
(IFN-c and IL-12) and downregulated Th2 cytokine responses (IL-
10 and IL-4) when compared to rLdHSP70 alone. This may be
attributed due to production of high amounts of IFN-c by cured
patients which in turn inhibit the production of IL-10 [73]. The
study corroborates the findings of Skeiky et al [74] wherein
recombinant HSP70 was effective in stimulating PBMCs from L.
braziliensis infected individuals to proliferate and produced IFN-c.
Encouraged with the observations made by in vitro study, we
further evaluated the protective efficacy of all the three combina-
tions in hamsters against L. donovani challenge. We noticed that
Figure 8. Cellular responses in vaccinated hamsters. LTT response (mean O.D value) to combinations and ConA in normal, infected control,
BCG control, rLdHSP70 control groups as well as in group 5–11 vaccinated hamsters (A) on days 45, and (B) on day 90 p.c. Significance values
indicate the difference between the vaccinated groups and infected group. NO production (mM) to LPS and combinations of rLdHSP70 in the naive
macrophages co-incubated with supernatants of mononuclear cells isolated from respective group of vaccinated hamsters in comparison to the
unimmunized infected controls, BCG immunized controls, rLdHSP70 control and uninfected normal hamsters (C) on day 45, and (D) on day 90 p.c.
DTH response (mm) to soluble L. donovani (SLD) as footpad swelling on day 90 p.c (E). Significance values indicate the difference between the
vaccinated groups and infected group (*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0108556.g008
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Figure 9. Splenic iNOS and cytokine (Th1/Th2) mRNA expression profile analysis of normal, infected, BCG or HSP70 control and
vaccinated hamsters (n =3/4) on day 45 and 90 p.c. by qRT-PCR. Splenic inducible nitric oxide synthase (iNOS) (A and B) and cytokines, IL-12
(C and D), IFN-c (E and F), IL-10 (G and H) and IL-4 (I and J) mRNA expression profile was assessed by qRT-PCR in all the experimental groups of
hamsters on days 45 and 90 p.c. Data are presented as means 6 S.D and are representative of two independent experiments with similar results.
Significance values indicate the difference between the vaccinated and infected group (*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0108556.g009
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on day 90 p.c, though, all the three combinations - LdHSP70 +
rLdPDI, rLdHSP70 + rLdTPI and rLdHSP70 + rLdEL-2 offered
resistance to L. donovani challenge to the tune of 70 to 80% in
hamsters, the most effective combination was LdHSP70 + rLdPDI
(80%). Moreover, among the vaccinated groups, LdHSP70 +
rLdPDI vaccinated animals survived longer to the lethal challenge
and remained healthy upto 10 months whereas the rLdHSP70 +
rLdTPI and rLdHSP70 + rLdEL-2 vaccinated animals could
survive upto six months only. This finding was similar when
compared with the animal groups receiving recombinant proteins
along with BCG as adjuvant, indicating the adjuvant/immuno-
modulatory like property of rLdHSP70.
Since, the immunogenicity of most antigens is highly limited in
its pure form, it is often necessary to add adjuvant in order to
achieve the desired immune responses (cellular and humoral
immune response) for the control of disease progression. Further, it
Figure 10. Antibody response in vaccinated hamsters. IgG (A and D) and its isotypes IgG1 (B and E) and IgG2 (C and F) in vaccinated hamsters
in comparison to the non-vaccinated infected hamsters on days 45 and 90 p.c. Serum samples were collected from different experimental groups of
hamsters at designated time points and assayed for specific IgG, IgG1, and IgG2 levels by ELISA. Data are presented as the absorbance at 492 nm and
are means 6 SD for 3–4 hamsters per group in triplicate wells. Data are representative of two independent experiments with similar results.
Significance values indicate the difference between the vaccinated and infected group (*, p,0.05; **, p,0.01; and ***, p,0.001).
doi:10.1371/journal.pone.0108556.g010
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is well known that adjuvant stimulates the appropriate T-cell
immunity for intracellular pathogens and HSPs are among the
molecules able to stimulate antigen-presenting cells to secrete pro-
inflammatory cytokines and strongly promote Th1 responses [75–
77]. Moreover, it can stimulate production of NO by macrophages
and up-regulation of co-stimulatory molecules that are required
for priming naive T-cells. Therefore, the independent immunos-
timulatory capacity of HSPs makes them an attractive agent for
the induction of specific immune responses as was observed in our
study. Increasing evidences have indicated important roles of
HSP70s, serving as carriers for antigens and promoting the
induction/release of cytokines by different immune cells [53,78–
80]. Earlier, several workers already explored the adjuvant
property of HSP70 molecule, eliciting strong humoral and cellular
immune response when used in combination with various antigens
in Leishmania parasite [22–24,57,65,68–71,81]. In the present
study, we have also exploited the adjuvant property of LdHSP70
alongwith the potential Th1-stimulatory proteins - rLdPDI,
rLdTPI and rLdEL-2 proteins and checked whether it can further
enhance their immunogenicity and protective responses.
Given that the development of strong cellular immune responses
like T-cell responses, NO production and DTH response imparts
major role in protection against parasite and is also supposed to
contribute to healing in VL [64,82–86]. All the hamsters
vaccinated with various combinations of rLdHSP70 and chal-
lenged with L. donovani exhibited enhanced proliferative response
than in non-vaccinated infected control animals. Further,
lymphocytes from all the vaccinated hamsters produced remark-
ably better level of NO in the macrophages of naive hamsters
which also supported the view regarding the up-regulation of
iNOS by Th1 cell-associated cytokines and confirm that the NO-
mediated macrophage effector mechanism is critical in the control
of parasite replication in the animal model [87,88]. Further, as
earlier reports have shown that successful vaccination of humans
and animals is often related to antigen-induced DTH responses in
vivo [36,89], in the present study, hamsters vaccinated with all the
three combinations have shown significant DTH response as
compared with other control groups which can be correlated with
disease progression in hamsters. Moreover, since, it has been well
established that the resistance against leishmaniasis is conferred by
Th1 cells while susceptibility is conferred by Th2 cells, these
cytokines were further checked by qRT-PCR. It was observed that
the vaccination of hamsters with all the three combinations
resulted in significant up-regulation of Th1 type of immune
response by day 90 p.c. The mRNA transcript level of IFN-c, a
signature cytokine of the Th1-type response, was found to be
highly up-regulated, particularly in LdHSP70 + rLdPDI vaccinat-
ed animals (,5 folds), over the infected control groups. Similarly,
the level of IL-12 was also elevated upto ,8 folds in LdHSP70 +
rLdPDI vaccinated animals and were highly down-regulated in
infected animals. However, there was no increase in the level of
key macrophage deactivating Th2 cytokines- IL-10 and IL-4,
which have a definitive association with an acute phase of VL
[36,90]. Moreover, the levels of IgG and IgG1 antibodies, whose
increase is directly proportional to the L. donovani loads [91], was
present at very low level in the serum samples of vaccinated
animals whereas the IgG2 titres were the highest in the vaccinated
animals and these observations were consistent with the develop-
ment of effective immune responses [37].
The major observation from this study was that L. donovani
rLdHSP70, yielded a specific Th1-like immune response in
lymphocytes of cured hamsters/cured patients and it induced
even stronger cellular response when was combined with all the
three Th1 stimulatory proteins. Moreover, all the three combina-
tions generated more or less similar immunoprotective response,
however, depending on the survival data, LdHSP70 + rLdPDI
appeared to be slightly better than the rLdHSP70 + rLdTPI and
rLdHSP70 + rLdEL-2. Microbial HSP have been implicated in
the induction of the innate and adaptive arms of the immune
response [92,93]. Among the various HSPs, HSP70 is one of the
most abundant chaperones therefore the additive effect may be
due to its chaperone activity.
There has been various HSP70-based vaccine strategies
described to enhance fusion vaccine potency [94], as it has strong
ability to complexes with antigenic peptides and can generate a
peptide-specific cellular immune response more efficient than the
peptide alone [93]. Since, HSP70 has been identified as one of the
Th1-stimulatory protein of Leishmania parasites, it could act as a
strong potentiator of the immune system and can be a better
alternative of BCG as an adjuvant which has several side effects.
Thus, it may be surmised that vaccines based on combination of
Leishmania HSP70 with Th1-stimulatory proteins can be of
relevance for future vaccination strategies against this intracellular
pathogen.
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